Using the reagents from the CEA-Roche kit, we found that solutions containing only glycosaminoglycans (GAG) yielded false concentrations of carcinoembryonic antigen (CEA), and mixtures of CEA and GAG produced falsely high values. On the other hand, solutions of GAG yielded no additional CEA concentration when reagents from the Abbott CEA kit were used; rather, the CEA result was decreased with the Abbott kit for a CEA solution also containing GAG. These effects of GAG were not ascribable to contamination, because neither gel filtration nor ion-exchange column chromatography separated the false Roche CEA content related to GAG from their peaks of uronic acid or from their anticoagulant activity. In addition, an enzyme specific for GAG eliminated these GAGderived false concentrations.
The procedure described by Hallen (13) was adopted with a slight modification. A 1.5 x 20 cm Pharmacia column packed with Cellex D was used. Elution was at room temperature with a linear gradient of lithium chloride (100 mL of 0.2 moL1L LiC1 and 100 mL of 3 molIL LiC1 in a 50 mmol/L sodium acetate buffer solution, pH 4). Samples were dialyzed against the sodium acetate buffer before being applied to the column. The eluate was dialyzed against water before being used for other determinations.
Methods for gel filtration chromatography and chromatography on Sepharose 4B have been described (3). Uronic acid was measured by the m-hydroxydiphenyl method of Blumenkrantz and Asboe-Hansen (14). Anticoagulant activity was evaluated with a Sigma "Heparin in Plasma" kit
(12).
Enzyme treatment.
To test whether chondroitin ABC lyase is also capable of removing chondroitin sulfates from solutions containing plasma proteins, we used the following conditions. The incubation mixture, total volume 1 mL, contained 0.5 mL of normal human plasma that had been dialyzed against water, 100 tg (20 jL) of chondroitin sulfate, 20 ng (160 zL) of Roche CEA standard, 2 units (40 L) of chondroitin ABC lyase, and 10 L of Tris . HCI buffer (pH 7.8), the last added to adjust the final volume. For the various controls, any substance not included was replaced by buffer. The same buffer was also used to prepare enzyme and chondroitin sulfate solutions. After a 2-h incubation at 37 #{176}C, 0.1-mL aliquots were withdrawn and mixed with 0.1 mL of 0.2 mol/L sodium acetate buffer, pH 5, before analysis by the Abbott CEA assay. Other 0.25-mL aliquots, after dialysis against water, were used for the Roche CEA assay (15). Heat and acid treatments.
To find out how much GAG could be removed by either perchlonc acid (final concentration 0.6 molIL) or heat (70 #{176}C, 15 mm) treatment, we used the following procedure.
The solutions contained 1 mL of normal human plasma that had been dialyzed against water, and various amounts of GAG in 10 mniol/L phosphate buffer, pH 7.4; the final volume was 2 mL. Aliquota were mixed with an equal volume of 0.1 mol/L sodium acetate buffer, pH 5, before heat treatment, or with an equal volume of 1.2 mol/L perchioric acid for acid treatment. Positive and Negative Effects of GAG in the Presence of CEA
Results

CEA
The effect of GAG on CEA measurements in the presence of CEA is also similar to that found earlier with heparin (3). Figure served with the Roche kit was caused by contaminants (Figures 3 and 4) . As in our findings with heparin, none of the peaks of false Roche kit CEA ascribable to GAG could be clearly separated from the peaks of anticoagulant activity or from the uronic acid peak characteristic of these GAG preparations. The chromatographic procedure used in Figure 4 is a method favored for separating and identifying GAG (13); most other biological molecules are not retained by the column at pH 4. Therefore, the association of the false Roche kit concentration of CEA with both the anticoagulant activity and the uronic acid concentration during GAG chromatography strongly supports the idea that these properties are derived from the same molecule.
As illustrated in
In addition, as Figure 5 shows, both the CEA standard of the Roche kit and CEA isolated from colon tumor appear at the void volume of the diethylaminoethylcellulose column, well separated from the false CEA peaks associated with the GAG. On the other hand, all the GAG tested in Figure 4 
Removal of GAG from Plasma
By heat and acid treatments.
Before CEA is determined in plasma, most of the plasma proteins, which interfere, must be removed. The methods used in the Abbott and Roche procedures are heat (70 #{176}C for 15 mm) and perchioric acid (0.6 mollL) treatments, respectively. We found that, in solutions containing GAG only, concentrations of uronic acid were unaffected by either treatment. However, when plasma proteins were present, both heat and perchionc acid could decrease the concentrations of the GAG.
In our initial experiments, we monitored the concentrations of GAG by use of a modified carbazole reaction 
By enzyme digestion.
To test whether an enzyme could be used effectively to remove GAG, we used chondroitin ABC lyase, which catalyzes digestion of hyaluronic acid and all chondroitin sulfates, to treat the solution containing the Moreover, because there was no loss in CEA concentration (with use of the Roche CEA standard) in either the Roche or the Abbott assay after enzyme treatment, we conclude that it is the GAG per se that produce the observed positive and negative effects on CEA assays.
Discussion
GAG are widely distributed in human physiological fluids and tissues (4) (5) (6) 17) .
Normal plasma contains as much as 5 to 10 .g of GAG per milliliter (5-8, 18, 19) , a concentration that may contribute from 1 to 2 ng of false CEA per milliliter with the Roche procedure, depending on the type of GAG involved. Urine from normal adults contains nearly 10 mg of GAG per 24-h urine (4), with greater amounts in urine from younger persons. Moreover, GAG concentrations increase in physiological fluids and tissues in several diseases (6, 8, 18, 19 The false CEA concentration produced by GAG probably is related to their acidic properties. For example, dextran sulfate, a synthetic anticoagulant, produces the greatest false CEA activity (Roche kit) per unit weight and also requires the greatest salt concentration to elute it from the column (Figure 5) . At pH 4, very few major plasma proteins carry a negative charge and are retained by the diethyl aminoethylcellulose column. The association of a low isoelectric point for a molecule with its false Roche CEA activity raises the question that perhaps other, non-GAG molecules in physiological fluids, because of their acidic nature, may also interfere with the binding between CEA and anti-CEA. Such molecules have not yet been detected, but various mucous substances and proteoglycans are probably good candidates (20). The only two commercially available kits for CEA assay are well known not to produce similar results for the same specimens (9-11). Although some of these differences are related to variations in the preparations of CEA and anti-CEA, to the ionic strength and pH of their assay conditions, and to sample preparation, they may also be related to the effects of the GAG on CEA determination (Figure 2) . The much higher concentration of CEA measured by the Roche direct procedure (21) may also be caused, at least in part, by
GAG interference.
Until a simpler and more economical way is found to remove GAG specifically from test specimens before CEA assay, we recommend the heat treatment used in the Abbott method. Such treatment should result in a substantially improved correlation between the two methods.
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